Neurologic manifestations in hospitalized patients with COVID-19
The ALBACOID registry

Carlos Manuel Romero-Sánchez, MD, Inmaculada Díaz-Maroto, MD, Eva Fernández-Díaz, MD, et al.

Cite as: Neurology® 2020;95:e1060-e1070. doi:10.1212/WNL.0000000000009937

Correspondence
Dr. Romero-Sánchez
carlosmanuelromerosanchez@gmail.com

Study objective
To study the frequency and characteristics of neurologic symptoms observed in patients hospitalized with coronavirus disease 2019 (COVID-19).

What is known and what this paper adds
Neurological symptoms have been reported in patients with COVID-19, including headache, dizziness, anosmia, and dysgeusia. This study found that more than half of patients hospitalized with COVID-19 have some neurologic manifestations.

Participants and setting
The study includes data from all the 841 patients (56.2% men; mean age, 66.4 ± 15.0 years) admitted to 2 hospitals in the Spanish province of Albacete during March, 2020 with COVID-19. All patients had confirmed infection with SARS-CoV-2 by throat swab PCR or identification of IgG/IgM antibodies in serum.

Design, size, and duration
This is a retrospective observational study. Electronic medical records, laboratory test results, radiology findings, and EEG and EMG recordings were reviewed to identify any neurological manifestations; these were classified as nonspecific symptoms (headache, dizziness or myalgia), neuropsychiatric disorders (insomnia, depression, anxiety or psychosis), central nervous system disorders (direct viral infection, disorders of consciousness, seizures and stroke), peripheral nervous system (PNS) disorders (cranial neuropathies, anosmia/dysgeusia, peripheral neuropathy), myopathy and de-myelinating events.

Primary outcome measures
The primary outcome was the proportion of patients who had neurologic manifestations.

Main results and the role of chance
In total, 483 patients (57.4%) had neurologic manifestations. Nonspecific symptoms such as myalgia (17.2%), headache (14.1%), and dizziness (6.1%) were mostly present in the early stages of infection. Anosmia (4.9%) and dysgeusia (6.2%) usually occurred early and were more common in less severe cases. Disorders of consciousness (19.6%) occurred mostly in severe cases and advanced stages. Other reported neurologic manifestations included myopathy (3.1%), dysautonomia (2.5%), cerebrovascular diseases (1.7%), seizures (0.7%), movement disorders (0.7%), encephalitis (n = 1), Guillain-Barré syndrome (n = 1), and optic neuritis (n = 1). Neurologic complications were the main cause of death in 4.1% of the patients who died.

Bias, confounding, and other reasons for caution
Pandemic conditions precluded full neurologic evaluations and diagnostic work-up for every patient.

Study funding/potential competing interests
This study received no funding. The authors report no competing interests. Go to Neurology.org/N for full disclosures.

Table: Associations between selected neurologic manifestations and COVID-19 severities

<table>
<thead>
<tr>
<th>Neurologic manifestation</th>
<th>Odds ratio (95% confidence interval) for severe cases vs nonsevere cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any</td>
<td>1.65 (1.2-2.2)</td>
</tr>
<tr>
<td>Disorders of consciousness</td>
<td>8.18 (5.5-12.2)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>0.63 (0.4-0.9)</td>
</tr>
<tr>
<td>Myopathy</td>
<td>9.13 (3.1-26.7)</td>
</tr>
<tr>
<td>Movement disorders</td>
<td>7.89 (0.9-67.8)</td>
</tr>
</tbody>
</table>

A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The corresponding author(s) of the full-length article and the journal editors edited and approved the final version.
Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry
Neurology 2020;95:e1060-e1070 Published Online before print June 1, 2020
DOI 10.1212/WNL.0000000000009937

This information is current as of June 1, 2020

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/95/8/e1060.full

References
This article cites 17 articles, 1 of which you can access for free at:
http://n.neurology.org/content/95/8/e1060.full#ref-list-1

Citations
This article has been cited by 7 HighWire-hosted articles:
http://n.neurology.org/content/95/8/e1060.full##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Clinical Neurology
http://n.neurology.org/cgi/collection/all_clinical_neurology
Cohort studies
http://n.neurology.org/cgi/collection/cohort_studies

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise

Neurology ® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2020 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.